drugset / Trial / NCT04966507

Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention

NCT04966507 ↗

RandomizedCrossoverDouble-blindPrevention

Summary

This study aims to determine acceptability and preliminary efficacy of daily use of an antibacterial mouthwash as compared to a placebo mouthwash in reducing the incidence of pharyngeal gonorrhea among a cohort of HIV-positive and high risk HIV-negative men. Investigators plan to test the following hypotheses: 1. Participants will maintain a high level of adherence and satisfaction with daily mouthwash use. Furthermore, the investigators hypothesize that barriers to adherence will include structural factors such as unstable housing and individual level factors such as substance use. 2. Participants receiving the antibacterial mouthwash will have a lower incidence of pharyngeal gonorrhea as compared to participants receiving the placebo mouthwash. Furthermore, the investigators hypothesize that these reductions will remain even after adjusting for other factors such as HIV-status and substance use.

Timeline

Start
2022-02-17
Primary completion
2025-05-16
Completion
2025-12-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Listerine Antiseptic Mouthwash Product Unknown 20 ml Other

Indications